

Maryam Karimi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9640042/publications.pdf>

Version: 2024-02-01

9
papers

185
citations

1478505

6
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

198
citing authors

#	ARTICLE	IF	CITATIONS
1	Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: In vitro and in vivo anti-tumor study. International Journal of Pharmaceutics, 2020, 580, 119211.	5.2	46
2	Design and development of vitamin C-encapsulated proliposome with improved <i>in-vitro</i> and <i>ex-vivo</i> antioxidant efficacy. Journal of Microencapsulation, 2018, 35, 301-311.	2.8	43
3	Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy. Life Sciences, 2020, 252, 117646.	4.3	28
4	Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide. Journal of Drug Targeting, 2021, 29, 617-630.	4.4	25
5	Spectrofluorometric Method Development and Validation for the Determination of Curcumin in Nanoliposomes and Plasma. Journal of Fluorescence, 2020, 30, 1113-1119.	2.5	20
6	Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model. Biotechnology Progress, 2021, 37, e3116.	2.6	16
7	Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx®: In vitro and in vivo evaluations. Colloids and Surfaces B: Biointerfaces, 2021, 207, 112012.	5.0	4
8	Efficacy Comparison of TAT Peptide-Functionalized PEGylated Liposomal Doxorubicin in C26 and B16F0 Tumor Mice Models. International Journal of Peptide Research and Therapeutics, 2021, 27, 2099-2109.	1.9	3
9	Antennapedia-derived positively charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin. Biotechnology Progress, 2021, 37, e3202.	2.6	0